Tecfidera May Reduce Relapse Rate More Than Other RRMS Therapies

Tecfidera May Reduce Relapse Rate More Than Other RRMS Therapies

306984

Tecfidera May Reduce Relapse Rate More Than Other RRMS Therapies

First-line treatment with Tecfidera (dimethyl fumarate) leads to a lower rate of relapses in people with relapsing-remitting multiple sclerosis (RRMS) than does treatment with Aubagio (teriflunomide) or injectable immunomodulators, according to an analysis of insurance data from France. “These data will be useful to feed into physician choices of patients’ treatment,” according to researchers. The findings were published in the British Journal of Clinical Pharmacology, in the study “Comparative effectiveness of dimethyl fumarate in Multiple Sclerosis.”…

You must be logged in to read/download the full post.